课题基金 / 基金详情

Structural Approach to Define New Functional Activities of Neutrophil Protein CAP37 in Neurodegenerative Diseases(Kasus-Jacobi)

Structural Approach to Define New Functional Activities of Neutrophil Protein CAP37 in Neurodegenerative Diseases(Kasus-Jacobi)
定义中性粒细胞蛋白 CAP37 在神经退行性疾病中新功能活性的结构方法(Kasus-Jacobi)
批准号:
9360241
负责人:
Anne Kasus-Jacobi
金额:
$20.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Anne Kasus-Jacobi的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要(Kasus-Jacobi项目) 淀粉样β蛋白(Aβ)和晚期糖基化终产物受体(RAGE)是 阿尔茨海默病(AD)的发病机制。没有临床干预措施来阻止或减缓疾病的进展 疾病是可以获得的,但一些临床试验显示在认知能力下降方面有令人鼓舞的结果 当β或RAGE作为靶点时,患有轻度疾病的患者,证明了 利用这些靶点进行AD治疗。我们最近发现,阳离子抗菌剂CAP37 蛋白,在AD患者的大脑中显著上调,结合和切割Aβ,并与 RAGE,提示CAP37参与了AD的发病机制。我们的长期目标是发展安全 针对Aβ、RAGE和CAP37的神经退行性疾病的有效治疗方法,如 广告。我们在本申请中的目标是定义CAP37的S相互作用的机制和结构方面 带着愤怒和β。拟议研究的基本原理是,更好地理解CAP37是如何 调控AD的发病机制将指导该病新药的开发。我们提出了两个具体的 目标。我们的第一个目标是定义CAP37-RAGE结合接口,并确定CAP37如何干扰 这种受体的其他配体的结合。我们对此目的的工作假设是CAP37结合了愤怒 通过与其他RAGE配体不同的区域。这可能会影响其他配体与RAGE的结合 通过受体的变构修饰。为此,我们将阐明CAP37和CAP37形成的复合体。 愤怒。成功完成这一目标将使我们能够1)提出CAP37与 RAGE相对于Aβ和其他RAGE配体,2)决定CAP37与RAGE的结合如何干扰 其他配体的结合,3)提出了CAP37可能激活RAGE的机制,以及4)如果 CAP37激活RAGE,确定具有抑制内源性CAP37治疗潜力的化合物 通过愤怒发出信号。我们的第二个目标是定义CAP37的S结合和 Aβ的切割,并确定CAP37是否干扰Aβ的聚合,这是最相关的 Aβ在AD中的形式。我们将确定CAP37是否与Aβ单体和/或有毒聚合物结合,以及 CAP37可阻止或逆转Aβ的毒性聚合。我们将定义CAP37的机制, 最初被预测为酶不活性,在Aβ上作为丝氨酸蛋白酶工作,并确定CAP37 能裂解聚合的Aβ。当我们的目标实现时,我们就会知道CAP37是通过什么机制 干扰Aβ-RAGE轴,导致更好地认识CAP37可能如何影响 AD的进展。这将使开发更好的治疗AD和其他神经退行性疾病的方法成为可能 涉及β和愤怒的疾病。
英文摘要
Project Summary (Kasus-Jacobi Project) Amyloid beta (Aβ) and the receptor for advanced glycation end-products (RAGE) are central to the pathogenesis of Alzheimer's disease (AD). No clinical intervention to stop or slow the progression of the disease is available, but a few clinical trials revealed encouraging results in terms of cognitive decline for patients with a mild form of the disease when Aβ or RAGE were targeted, demonstrating the validity of exploiting these targets for AD treatment. We have recently discovered that CAP37, a cationic antimicrobial protein, is significantly up regulated in the brains of patients with AD, binds and cleaves Aβ, and interacts with RAGE, which suggests that CAP37 modulates the pathogenesis of AD. Our long-term goal is to develop safe and effective therapeutic approaches targeting Aβ, RAGE and CAP37 for neurodegenerative diseases such as AD. Our objective in this application is to define the mechanistic and structural aspects of CAP37's interactions with RAGE and Aβ. The rationale for the proposed research is that a better understanding of how CAP37 regulates AD pathogenesis will guide the development of new drugs for the disease. We propose two specific aims. Our first aim is to define the CAP37-RAGE binding interface and determine how CAP37 interferes with the binding of other ligands of this receptor. Our working hypothesis for this aim is that CAP37 binds RAGE through a different domain than the other RAGE ligands. This may affect the binding of other ligands to RAGE through allosteric modification of the receptor. In this aim, we will elucidate the complex formed by CAP37 and RAGE. Successful completion of this aim will allow us to 1) propose a model for the binding of CAP37 to RAGE relative to Aβ and other RAGE ligands, 2) determine how the binding of CAP37 to RAGE interferes with the binding of other ligands, 3) propose a mechanism for a possible activation of RAGE by CAP37, and 4) if CAP37 activates RAGE, identify compounds with therapeutic potential for inhibition of endogenous CAP37 signaling through RAGE. Our second aim is to define the structural determinants of CAP37's binding and cleavage of Aβ and determine if CAP37 interferes with the polymerization of Aβ, which is the most relevant form of Aβ in AD. We will determine if CAP37 binds Aβ monomers and/or toxic polymers, and if the binding of CAP37 prevents or reverses the toxic polymerization of Aβ. We will define the mechanism by which CAP37, originally predicted to be enzymatically inactive, operates as a serine protease on Aβ, and determine if CAP37 can cleave polymerized Aβ. When our aims are accomplished, we will know the mechanisms by which CAP37 interferes with the Aβ-RAGE axis, leading to a better appreciation of how CAP37 might influence the progression of AD. This will allow the development of better therapeutics for AD and other neurodegenerative diseases involving Aβ and RAGE.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Wound healing mechanisms modulated by novel antimicrobial Peptides
PHOTORECEPTOR RETINOL DEHYDROGENASES AND VISION
PHOTORECEPTOR RETINOL DEHYDROGENASES AND VISION
Detoxification Role of Retinol Dehydrogenases RDH11 and RDH12
海外基金